Heart FailureYale-HFNCT04237701
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
An observational study of Heart Failure and Heart Failure With Reduced Ejection Fraction, run by Yale University at 1 site in United States.
Trial summary
The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- How many people
- 40,000 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2019to 30 Dec 2030
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
Who may be able to join
- Seen within the Yale New Haven Health System
- Diagnosis of heart failure
Who cannot join
- Age<18
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Nihar Desai, MD MPH contact
United States1 site, 1 recruiting
- Recruiting
Yale New Haven Health System
New Haven, Connecticut, 06510
Tariq Ahmad, MD MPH, 203-843-1667, tariq.ahmad@yale.edu
Nihar Desai, MD MPH, 2037676399, nihar.desai@yale.edu
About this study
Official title: Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.
Read the detailed description
Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure NYHA Class IV
- Medical subject headings
- Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants hospitalized for heart failure
Heart Failure hospitalizations
Measured: 10 years
Doses of therapies that comprise guideline directed medical therapy
Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2020
- Study start1 Oct 2019
- Primary completion30 Dec 2030 (estimated)
- Study completion30 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 40,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nihar Desai, MD MPH, Study director, Yale UniversityTariq Ahmad, MD MPH, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04237701
- Sponsor's protocol ID
- 2000026771
- Other IDs
- No NIH funding
- Acronym
- Yale-HF
- Status last verified
- Mar 2026
- First submitted
- 17 Jan 2020
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data is on patients seen at Yale New Haven Health system and will be used for quality improvement.
Publications
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 May 21;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015. Epub 2019 Mar 4.
PubMed 30844480Ahmad T, Desai NR. Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. Circ Cardiovasc Qual Outcomes. 2022 Apr;15(4):e008292. doi: 10.1161/CIRCOUTCOMES.121.008292. Epub 2022 Mar 11. No abstract available.
PubMed 35272506
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
- ClinicalTrials.gov ID
- NCT04237701
- Acronym / sponsor ID
- Yale-HF / 2000026771
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure NYHA Class IV
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40,000 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 30 Dec 2030 (estimated)
- Study completion
- 30 Dec 2030 (estimated)
- First posted
- 23 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.
Detailed description
Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
Key inclusion criteria (2 listed)
- Seen within the Yale New Haven Health System
- Diagnosis of heart failure
Key exclusion criteria (1 listed)
- Age<18
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants hospitalized for heart failure
Time frame: 10 years
Heart Failure hospitalizations
Doses of therapies that comprise guideline directed medical therapy
Time frame: 10 years
Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Results publication: PubMed 30844480Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 May 21;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015. Epub 2019 Mar 4.
- Derived from this study: PubMed 35272506Ahmad T, Desai NR. Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. Circ Cardiovasc Qual Outcomes. 2022 Apr;15(4):e008292. doi: 10.1161/CIRCOUTCOMES.121.008292. Epub 2022 Mar 11. No abstract available.
- Individual participant dataSharing planned: No. Data is on patients seen at Yale New Haven Health system and will be used for quality improvement.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nihar Desai, MD MPH contact
Nihar Desai, MD MPH study director
Yale University
Tariq Ahmad, MD MPH principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure and Heart Failure With Reduced Ejection Fraction, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tariq Ahmad, MD MPH ((203) 843-1667, Tariq.ahmad@yale.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants hospitalized for heart failure (time frame: 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04237701, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.